TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services

April 27, 2023

https://www.globenewswire.com/news-release/2023/04/27/2656215/8790/en/TG-Therapeutics-Announces-Issuance-of-Permanent-J-Code-for-BRIUMVI-ublituximab-xiiy-from-Centers-for-Medicare-and-Medicaid-Services.html

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Under the Healthcare Common Procedure Coding System (HCPCS), the BRIUMVI J-Code (J2329) will become effective July 1, 2023.

Read more at globenewswire.com

Related news for (TGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.